Eiger Biopharmaceuticals’ (EIGR) “Buy” Rating Reaffirmed at Wedbush

Eiger Biopharmaceuticals (NASDAQ:EIGR)‘s stock had its “buy” rating restated by analysts at Wedbush in a report issued on Tuesday. They presently have a $43.00 price objective on the biotechnology company’s stock. Wedbush’s target price indicates a potential upside of 226.25% from the stock’s current price.

A number of other equities analysts also recently weighed in on EIGR. BidaskClub downgraded shares of Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Tuesday, February 5th. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Robert W. Baird began coverage on shares of Eiger Biopharmaceuticals in a report on Monday, January 28th. They issued an “outperform” rating and a $47.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Eiger Biopharmaceuticals presently has a consensus rating of “Buy” and an average price target of $31.88.

EIGR traded down $0.10 during trading on Tuesday, reaching $13.18. 41,200 shares of the stock were exchanged, compared to its average volume of 111,976. The company has a market cap of $251.22 million, a price-to-earnings ratio of -2.71 and a beta of 1.67. Eiger Biopharmaceuticals has a twelve month low of $8.20 and a twelve month high of $18.00. The company has a current ratio of 4.59, a quick ratio of 4.59 and a debt-to-equity ratio of 0.56.



In related news, Director Eldon C. Mayer III acquired 6,000 shares of the firm’s stock in a transaction on Wednesday, November 28th. The shares were purchased at an average cost of $10.07 per share, for a total transaction of $60,420.00. Following the completion of the acquisition, the director now directly owns 7,500 shares in the company, valued at $75,525. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Eldon C. Mayer III acquired 7,500 shares of the firm’s stock in a transaction on Monday, November 26th. The stock was bought at an average price of $9.75 per share, for a total transaction of $73,125.00. Following the completion of the acquisition, the director now owns 7,500 shares of the company’s stock, valued at $73,125. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 23,727 shares of company stock worth $242,953. Corporate insiders own 7.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in shares of Eiger Biopharmaceuticals in the fourth quarter valued at about $114,000. Dimensional Fund Advisors LP acquired a new position in shares of Eiger Biopharmaceuticals in the third quarter valued at about $194,000. Tocqueville Asset Management L.P. acquired a new position in shares of Eiger Biopharmaceuticals in the third quarter valued at about $203,000. Bank of New York Mellon Corp grew its stake in shares of Eiger Biopharmaceuticals by 36.8% in the second quarter. Bank of New York Mellon Corp now owns 20,412 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 5,492 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Eiger Biopharmaceuticals in the fourth quarter valued at about $255,000. Hedge funds and other institutional investors own 50.65% of the company’s stock.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.